Buy or sell Abpro stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Abpro Stock

Abpro is a biotechnology company focused on therapeutics, diagnostics, and research.

About Abpro Stock

Abpro is a biotechnology company dedicated to accelerating biological research by providing superior tools to researchers worldwide. As a pioneer of industrial biochemistry and an emerging leader in the reagents field, they have developed a proprietary technology platform that allows for faster, more efficient production of recombinant proteins and antibodies. As a result, Abpro delivers superior quality products at industry-leading speeds. Abpro leveraging these platforms, both independently and through collaborations with global pharmaceutical companies and research institutions to develop therapeutic antibodies for use in immuno-oncology, ophthalmology, and other disease areas. The DiversImmune platform enables the generation of novel antibodies and next-generation antibody therapies.

Funding History

March 2016$12.4M
April 2017$10.0M
January 2020$18.0M
April 2022$2.0M

Management

CEO & CO-FOUNDER

Eugene Cha

SVP OF STRATEGIC ALLIANCES

John Xu

Chairman & CEO

Ian Chan

CMO & SVP

Robert J. Markelewicz

Join 290K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo